Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone

被引：0
|
作者：
Mathews, Maju [1 ]
Pei, Huiling [1 ]
Savitz, Adam [1 ]
Nuamah, Isaac [1 ]
Elefant, Erica [1 ]
Hough, David [1 ]
Alphs, Larry [1 ]
Gopal, Srihari [1 ]
机构：
[1] Janssen Res & Dev, Titusville, NJ USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PM409
引用
收藏
页码：197 / 198
页数：2
相关论文
共 50 条
  • [41] A case report of pregnancy and paliperidone palmitate 3-monthly long-acting injection
    de Azevedo Avelar, Rita
    Luengo Corbal, Antonio
    Heitor, Maria Joao
    CLINICAL CASE REPORTS, 2020, 8 (12): : 2592 - 2594
  • [42] Patient reported outcomes from schizophrenia patients treated with paliperidone palmitate 1-monthly for at least 6 months (picture study)
    Vega, M.
    Arques, S.
    Herrera, B.
    Garcia-Dorado, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S944 - S945
  • [43] ONCE-MONTHLY PALIPERIDONE PALMITATE COMPARED WITH ORAL ATYPICAL ANTIPSYCHOTIC TREATMENT IN PATIENTS WITH SCHIZOPHRENIA
    Kim, E.
    Starr, H. L.
    Bossie, C.
    Mao, Lian
    Alphs, L.
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S318 - S318
  • [44] Long term impact of 3-monthly paliperidone palmitate on hospitalisation in patients with schizophrenia: Six-year mirror image study
    Clark, Ivana
    Wallman, Phoebe
    Gee, Siobhan
    Taylor, David
    ACTA PSYCHIATRICA SCANDINAVICA, 2024, 150 (01) : 48 - 50
  • [45] Clinical outcomes with paliperidone palmitate 3-monthly injection as monotherapy: observational 3-year follow-up of patients with schizophrenia
    Clark, Ivana
    Wallman, Phoebe
    Gee, Siobhan
    Taylor, David
    EUROPEAN PSYCHIATRY, 2024, 67 (01)
  • [46] Health-Care Utilisation and Costs of Transition from Paliperidone Palmitate 1-Monthly to 3-Monthly Treatment for Schizophrenia: A Real-World, Retrospective, 24-Month Mirror-Image Study
    Chang, Bo-Chieh
    Kuo, Meng-Hsuan
    Lee, Chi-Hui
    Chu, Ya-Lan
    Chen, Kuang-Peng
    Tung, Chun-Liong
    Yang, Ya-Hui
    Hung, Chuan-Sheng
    Tsai, Jui-Hsiu
    Chuang, Hung-Yi
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2024, 20
  • [47] Use of palmitate of paliperidone 1-monthly in patients <40 years old: Results of real clinical practice
    Campos, J. A.
    Docasar, L.
    Seoane, A. M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S535 - S535
  • [48] PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION IN SCHIZOPHRENIA: BASELINE INTERIM ANALYSIS OF A NATURALISTIC, 52-WEEK, PROSPECTIVE STUDY
    Hargarter, L.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    Peters, K.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 : 143 - 144
  • [49] COST CONSEQUENCE OF INTRODUCING PALIPERIDONE PALMITATE 3-MONTHLY FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN THE ENGLISH NATIONAL HEALTH SERVICE (NHS)
    Ming, T.
    Rao, B.
    Bird, A.
    VALUE IN HEALTH, 2017, 20 (09) : A710 - A711
  • [50] Paliperidone palmitate 3-monthly formulation in schizophrenia - baseline interim analysis of a naturalistic, 52-week, prospective study
    Hargarter, L.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S950 - S950
12345